Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Updates from the NHLBI-MDS Natural History study

Mikkael Sekeres • 11 Dec 2021
ASH 2021
Myelodysplastic Syndromes
NHLBI-MDS

In this video, Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the NHLBI-MDS Natural History Study (NCT02775383), which is a prospective study that aims to collect valuable data from patients with myelodysplastic syndromes (MDS), and build a detailed biorepository to allow for a better understanding of this disease. Dr Sekeres then draws focus on the outcomes of MDS patients in this study who contracted COVID-19, and how vaccination may impact the future of these patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

More from Mikkael Sekeres

1:20
Outcomes for Hispanic patients with ALL treated at centers across the US
Mikkael Sekeres • 11 Dec 2021
1:58
Updates from the PANTHER trial
Mikkael Sekeres • 11 Dec 2021
1:34
Exciting news at the ASH 2021 plenary scientific session
Mikkael Sekeres • 6 Dec 2021
2:09
Trends in AML and MDS at ASH 2021
Mikkael Sekeres • 6 Dec 2021

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals